These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1284 related articles for article (PubMed ID: 30546055)

  • 21. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
    J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma.
    Nallet-Staub F; Marsaud V; Li L; Gilbert C; Dodier S; Bataille V; Sudol M; Herlyn M; Mauviel A
    J Invest Dermatol; 2014 Jan; 134(1):123-132. PubMed ID: 23897276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insights into the Regulation of Yap/Taz from Cellular Systems and Mouse Models.
    Du W; Du W; Wan M; Zhou X; Xu X; Zheng L
    Curr Stem Cell Res Ther; 2018; 13(1):16-25. PubMed ID: 28042766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Hippo pathway effectors TAZ/YAP regulate dicer expression and microRNA biogenesis through Let-7.
    Chaulk SG; Lattanzi VJ; Hiemer SE; Fahlman RP; Varelas X
    J Biol Chem; 2014 Jan; 289(4):1886-91. PubMed ID: 24324261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin.
    Rognoni E; Walko G
    Cells; 2019 May; 8(5):. PubMed ID: 31058846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Hippo Pathway as Drug Targets in Cancer Therapy and Regenerative Medicine.
    Nagashima S; Bao Y; Hata Y
    Curr Drug Targets; 2017; 18(4):447-454. PubMed ID: 26758663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Arterial Wall Stress Induces Phenotypic Switching of Arterial Smooth Muscle Cells in Vascular Remodeling by Activating the YAP/TAZ Signaling Pathway.
    Wang Y; Cao W; Cui J; Yu Y; Zhao Y; Shi J; Wu J; Xia Z; Yu B; Liu J
    Cell Physiol Biochem; 2018; 51(2):842-853. PubMed ID: 30466081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hippo pathway coactivators Yap and Taz are required to coordinate mammalian liver regeneration.
    Lu L; Finegold MJ; Johnson RL
    Exp Mol Med; 2018 Jan; 50(1):e423. PubMed ID: 29303509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.
    Johnson R; Halder G
    Nat Rev Drug Discov; 2014 Jan; 13(1):63-79. PubMed ID: 24336504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?
    Shreberk-Shaked M; Oren M
    Mol Oncol; 2019 Jun; 13(6):1335-1341. PubMed ID: 31050214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hippo-YAP/TAZ signalling coordinates adipose plasticity and energy balance by uncoupling leptin expression from fat mass.
    Choi S; Kang JG; Tran YTH; Jeong SH; Park KY; Shin H; Kim YH; Park M; Nahmgoong H; Seol T; Jeon H; Kim Y; Park S; Kim HJ; Kim MS; Li X; Bou Sleiman M; Lee E; Choi J; Eisenbarth D; Lee SH; Cho S; Moore DD; Auwerx J; Kim IY; Kim JB; Park JE; Lim DS; Suh JM
    Nat Metab; 2024 May; 6(5):847-860. PubMed ID: 38811804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.
    Dey A; Varelas X; Guan KL
    Nat Rev Drug Discov; 2020 Jul; 19(7):480-494. PubMed ID: 32555376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 34. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
    Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer.
    Baroja I; Kyriakidis NC; Halder G; Moya IM
    Nat Commun; 2024 Mar; 15(1):2700. PubMed ID: 38538573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
    Kim MH; Kim J
    Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
    Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
    Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Hippo pathway transcription factors YAP and TAZ play HPV-type dependent roles in cervical cancer.
    Patterson MR; Cogan JA; Cassidy R; Theobald DA; Wang M; Scarth JA; Anene CA; Whitehouse A; Morgan EL; Macdonald A
    Nat Commun; 2024 Jul; 15(1):5809. PubMed ID: 38987584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hippo pathway effector Yap promotes cardiac regeneration.
    Xin M; Kim Y; Sutherland LB; Murakami M; Qi X; McAnally J; Porrello ER; Mahmoud AI; Tan W; Shelton JM; Richardson JA; Sadek HA; Bassel-Duby R; Olson EN
    Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13839-44. PubMed ID: 23918388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.